This article presents a bullish theory on Amgen Inc. (AMGN), based on an options trade involving the sale of put contracts, signaling confidence in the stock’s floor. The thesis is supported by Amgen’s strong Q4 performance, 2026 revenue guidance, growth in Repatha, and the potential of its obesity candidate MariTide. The current valuation, especially considering the options premium, suggests a compelling entry multiple for a diversified biotech leader.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Amgen Inc. (AMGN): A Bull Case Theory
This article presents a bullish theory on Amgen Inc. (AMGN), based on an options trade involving the sale of put contracts, signaling confidence in the stock’s floor. The thesis is supported by Amgen’s strong Q4 performance, 2026 revenue guidance, growth in Repatha, and the potential of its obesity candidate MariTide. The current valuation, especially considering the options premium, suggests a compelling entry multiple for a diversified biotech leader.